Results of a phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma who failed to a platinum-based chemotherapy
Chan, A.T.; Hsu, M.M.; Goh, B.C.; Ma, B.B.; Liu, T.W.; Millward, M.; Chang, A.; Mueser, M.; Amellal, N.; Bessa, E.
EJC Suppls 1(5): S203-S204
2003
Accession: 035661527
PDF emailed within 1 workday: $29.90
Related References
Chan, A.T.C.; Hsu, M.-M.; Goh, B.C.; Hui, E.P.; Liu, T.-W.; Millward, M.J.; Hong, R.-L.; Whang-Peng, J.; Ma, B.B.Y.; To, K.F.; Mueser, M.; Amellal, N.; Lin, X.; Chang, A.Y. 2005: Multicenter, phase Ii study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(15): 3568-3576Baselga, J.é; Trigo, J.é M.; Bourhis, J.; Tortochaux, J.; Cortés-Funes, H.án.; Hitt, R.; Gascón, P.; Amellal, N.; Harstrick, A.; Eckardt, A.é 2005: Phase Ii multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(24): 5568-5577
Tao, C.-J.; Zhang, P.; Zhou, L.; Hu, Q.-Y.; Chen, X.-Z. 2020: Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy Translational Cancer Research 9(10): 6392-6401
Yoshino, T.; Hasegawa, Y.; Takahashi, S.; Monden, N.; Homma, A.; Okami, K.; Onozawa, Y.; Fujii, M.; Taguchi, T.; de Blas, B.; Beier, F.; Tahara, M. 2013: Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase Ii trial Japanese Journal of Clinical Oncology 43(5): 524-531
Peng, P.; Ou, X.; Liao, H.; Liu, Y.; Wang, S.; Cheng, Z.; Lin, Z. 2016: Phase Ii study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy Therapeutic Advances in Medical Oncology 8(3): 153-159
Péron, J.; Ceruse, P.; Lavergne, E.; Buiret, G.; Pham, B.-N.; Chabaud, S.; Favier, B.; Girodet, D.; Zrounba, P.; Ramade, A.; Fayette, J.ér.ôm. 2012: Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma Anti-Cancer Drugs 23(9): 996-1001
Tsakonas, G.; Specht, L.; Kristensen, C.A.; Moreno, M.H.C.; Cange, H.H.; Soderstrom, K.; Friesland, S. 2020: Randomized Phase Ii Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial) Cancers 12(11)
Chua, D.T.T.; Sham, J.S.T.; Au, G.K.H. 2003: A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy Oral Oncology (1997) 39(4): 361-366
You, B.; Tourneau, C.L.; Chen, E.X.; Chin, S.F.; Wang, L.; Jarvi, A.; Bharadwaj, R.R.; Kamel-Reid, S.; Perez-Ordonez, B.; Siu, L.L. 2009: A phase Ii trial of erlotinib after gemcitabine plus platinum-based chemotherapy in patients (pts) with recurrent and/or metastatic nasopharyngeal carcinoma (Npc) European Journal of Cancer Suppls 7(2): 478-479
Chua, D.T.T.; Sham, J.S.T.; Au, G.K.H. 2003: A phase Ii study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy Oral Oncology 39(4): 361-366
Hecht, M.; Hahn, D.; Wolber, P.; Hautmann, M.; Reichert, D.; Weniger, J.; Belka, C.; Bergmann, T.; Göhler, T.; Welslau, M.K.; Hofmann, D.; Fiektkau, R. 2018: Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii379-Viii380
Ueda, Y.; Enokida, T.; Okano, S.; Fujisawa, T.; Ito, K.; Tahara, M. 2020: Combination Treatment with Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients with Recurrent and/or Metastatic Nasopharyngeal Carcinoma Frontiers in Oncology 10: 571304
Sato, H.; Tsukahara, K.; Okamoto, I.; Katsube, Y.; Shimizu, A.; Kondo, T.; Hanyu, K.; Fushimi, C.; Okada, T.; Miura, K. 2019: Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients Acta Oto-Laryngologica 139(2): 201-205
You, B.; Le Tourneau, C.; Chen, E.X.; Wang, L.; Jarvi, A.; Bharadwaj, R.R.; Kamel-Reid, S.; Perez-Ordonez, B.; Mann, V.; Siu, L.L. 2012: A Phase Ii trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma American Journal of Clinical Oncology 35(3): 255-260
Zhu, Y.; Yang, S.; Zhou, S.; Yang, J.; Qin, Y.; Gui, L.; Shi, Y.; He, X. 2020: Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma Therapeutic Advances in Medical Oncology 12: 1758835920953738
Lim, C.M.; Liou, A.; Poon, M.; Koh, L.P.; Tan, L.K.; Loh, K.S.; Petersson, B.F.; Ting, E.; Campana, D.; Goh, B.C.; Shimasaki, N. 2022: Phase i study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma Cancer Immunology Immunotherapy: Cii 71(9): 2277-2286
Saba, N.F.; Hurwitz, S.J.; Magliocca, K.; Kim, S.; Owonikoko, T.K.; Harvey, D.; Ramalingam, S.S.; Chen, Z.; Rogerio, J.; Mendel, J.; Kono, S.A.; Lewis, C.; Chen, A.Y.; Higgins, K.; El-Deiry, M.; Wadsworth, T.; Beitler, J.J.; Shin, D.M.; Sun, S.-Y.; Khuri, F.R. 2014: Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck Cancer 120(24): 3940-3951
Zhang, Y.; Zhao, L.; Huang, P.; Wu, J.; Wang, F.; Huang, Y.; Zhang, L. 2012: Open-label, single-arm phase Ii study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy Cancer ChemoTherapy and Pharmacology 70(4): 611-615
Hanna, N.H. 2008: Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy Yearbook of Oncology 2008: 219-221
Vermorken, J.B.; Trigo, J.é; Hitt, R.; Koralewski, P.; Diaz-Rubio, E.; Rolland, F.éd.ér.; Knecht, R.; Amellal, N.; Schueler, A.; Baselga, J.é 2007: Open-label, uncontrolled, multicenter phase Ii study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(16): 2171-2177